Ignite Creation Date:
2025-12-24 @ 9:50 PM
Ignite Modification Date:
2026-04-02 @ 6:28 AM
Study NCT ID:
NCT05804032
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-07
First Post:
2023-03-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy with Either Intravenous or Subcutaneous Isatuximab in Patients with Newly Diagnosed Multiple Myeloma
Sponsor:
University of Heidelberg Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
GMMG-HD8/DSMM XIX
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None